1 not yet recruiting. 1 Phase 1.
| Phase | Trials | Status |
|---|---|---|
| Phase 1 | 1 | Not yet recruiting 1 |
Follow Daniel Breadner: new trials by email
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| ATRA and SDK002 in Combination With Chemotherapy and Anti-PD-1 Inhibitor in Patients With Advanced Pancreatic Ductal Adenocarcinoma. ATRA, Arsenic Trioxide (ATO), Gemcitabine - Advanced Pancreatic Ductal Adenocarcinoma | Phase 1 | Not yet recruiting | Daniel Breadner | 10 | 2026-02-15 | 2026-01-16 |
130-nm albumin-bound paclitaxel (1) · Arsenic Trioxide (1) · Gemcitabine (1) · Tretinoin (1) · tislelizumab (1)
Canada (1)